In8bio Inc (INAB)

NASDAQ
7.00
-1.09(-13.47%)
After Hours
7.55
+0.55(+7.86%)
- Real-time Data
  • Volume:
    42,457
  • Bid/Ask:
    7.00/7.55
  • Day's Range:
    7.00 - 8.73

INAB Overview

Prev. Close
8.09
Day's Range
7-8.73
Revenue
-
Open
8.24
52 wk Range
6.1-10.32
EPS
-0.42
Volume
42,457
Market Cap
131.28M
Dividend (Yield)
N/A
(N/A)
Average Volume (3m)
86,320
P/E Ratio
-
Beta
-
1-Year Change
-
Shares Outstanding
18,754,553
Next Earnings Date
Dec. 01, 2021
What is your sentiment on In8bio Inc?
or
Market is currently closed. Voting is open during market hours.

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong SellStrong SellStrong SellSellNeutral
Technical IndicatorsSellStrong SellStrong SellStrong SellStrong Buy
SummaryStrong SellStrong SellStrong SellStrong SellBuy

In8bio Inc Company Profile

In8bio Inc Company Profile

Employees
7

IN8bio, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of gamma-delta T cell therapies for the treatment of cancers. The company develops INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of solid tumors; and INB-100, an allogeneic product candidate, which is in Phase I clinical trial to treat patients with acute leukemia undergoing hematopoietic stem cell transplantation. It also develops INB-400 and INB-300 that is in preclinical Phase for treatment of various solid tumor cancers. The company was formerly known as Incysus Therapeutics, Inc. and changed its name to IN8bio, Inc. in August 2020. IN8bio, Inc. was incorporated in 2016 and is headquartered in New York, New York.

Read More
    Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
    Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.